Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evaxion ASEVAX +1.28%52 PB Ratio is 2.81 as of Sep. 09, 2026, which is 4% below its 10-year median of 2.92. GuruFocus rates EVAX with a GF Score™ of 52/100 and a GF Value™ of $3.34 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,215 Biotechnology companies, Evaxion AS ranks better than 53.09% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-09), Evaxion AS's share price is $3.21. Evaxion AS's Book Value per Share for the quarter that ended in Jun. 2026 was $1.14. Hence, Evaxion AS's PB Ratio of today is 2.81.
The historical rank and industry rank for Evaxion AS's PB Ratio or its related term are showing as below:
EVAX'
s PB Ratio Range Over the Past 10 Years
Min: 0.8 Med: 2.92 Max: 230.47
Current: 2.81
During the past 9 years, Evaxion AS's highest PB Ratio was 230.47. The lowest was 0.80. And the median was 2.92.
EVAX's PB Ratio is ranked better than 53.09% of 1215
companies
in the Biotechnology industry
Industry Median: 2.99
vs EVAX: 2.81
During the past 12 months, Evaxion AS's average Book Value Per Share Growth Rate was 15.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -50.80% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Evaxion AS was 40.30% per year. The lowest was -50.80% per year. And the median was -15.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Evaxion AS PB Ratio Related Terms
Evaxion AS PB Ratio Historical Data
* Premium members only.
The historical data trend for Evaxion AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Evaxion AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evaxion AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evaxion AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Evaxion AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Evaxion AS's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Evaxion AS (EVAX) has a PB Ratio of 2.81 as of Sep. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Evaxion AS and its competitors. This is near median its historical median of 2.92. Over the past decade, Evaxion AS's PB Ratio has ranged from 0.80 to 230.47. According to the industry distribution chart, Evaxion AS ranks #570 out of 1215 companies in the Biotechnology industry, placing it in the top 46.9%.
Is Evaxion AS's PB Ratio too high?
Evaxion AS's current PB Ratio of 2.81 is near median its 10-year median of 2.92. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 230.47. The Biotechnology industry median PB Ratio is 2.99. Evaxion AS's value of 2.81 is 6% below this industry median. Based on the distribution chart, Evaxion AS ranks #570 out of 1215 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Evaxion AS has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's PB Ratio compare to DYAI and ATOS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #570 out of 1215 companies for PB Ratio. This puts Evaxion AS in the upper half of its industry. The industry median PB Ratio is 2.99. Evaxion AS's value of 2.81 is 6% below this benchmark. Historically, Evaxion AS's own PB Ratio has ranged from 0.80 to 230.47 over the past decade. While the company's 10-year median is 2.92 vs. the industry median of 2.99, Evaxion AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,215 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evaxion AS's current PB Ratio of 2.81 is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Evaxion AS and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evaxion AS's current PB Ratio is 2.81, which is near median its own 10-year median of 2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Based on GuruFocus' analysis, Evaxion AS (EVAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.34, compared to a current price of $3.21 — trading 3.9% below its estimated fair value. The current PB Ratio is 2.81, which is near median its 10-year median of 2.92 and 6% below the Biotechnology industry median of 2.99. Evaxion AS's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Evaxion AS (EVAX), the current PB Ratio is 2.81 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evaxion AS (EVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Evaxion AS stock appears to be undervalued.
The current stock price of $3.21 is trading 3.9% below its estimated GF Value™ of $3.34.
GuruFocus considers Evaxion AS to be Fairly Valued.
Key valuation signals for EVAX:
PB Ratio: 2.81 (near median its 10-year median of 2.92)
GF Value™: $3.34 vs. price of $3.21 (3.9% below fair value)
Industry Position: 6% below the Biotechnology median (#570 of 1215)
No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
52GF Score
Get the complete analysis for EVAX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVAX has been successfully added to your 
